Terminology Service for NFDI4Health
All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Negative Regulation of Myeloid Cell Activation | NCIT_C40850 | [Myeloid Cell Suppression involves interference with, or restraint of, the production and activity of myeloid cells.] |
| Negative Regulation of Immune Cell Activation | NCIT_C40844 | [Immune Cell Suppression consists of interference with, or restraint of, the activity of one or more lymphoid or myeloid cell types associated with the immune response.] |
| PI3K/mTOR Kinase Inhibitor VS-5584 | NCIT_C112497 | [A potent and selective inhibitor of both phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor VS-5584 inhibits mTOR kinase and all class I PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR is a serine/threonine kinase downstream of PI3K, which also has PI3K-independent activity. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.] |
| Extended Release Flucytosine | NCIT_C112498 | [An extended release (ER) oral tablet that contains flucytosine (5-FC), a fluorinated cytosine analog, with antifungal activity and potential anti-cancer activity. Following oral administration of ER 5-FC, the 5-FC is deaminated to its active metabolite 5-fluorouracil (5-FU). 5-FU replaces uracil during RNA synthesis, which consequently inhibits downstream protein synthesis. In addition, 5-FU is metabolized further to 5-fluorodeoxyuridylic acid monophosphate, which inhibits thymidylate synthetase. Inhibition of this enzyme interrupts nucleotide synthesis, DNA replication and cell proliferation. Negative regulation of protein synthesis, DNA replication and cell proliferation can lead to cell death. Following ingestion of ER 5-FC, intravenous injection of a retroviral vector encoding cytosine deaminase (TC 511) at a tumor site may result in higher local concentrations of 5-FU and its metabolites, and increased tumor cell death than other 5-FU treatment regimens.] |
| Pyrimidine Antagonist | NCIT_C1557 | [An antimetabolite that affects the metabolism and utilization of pyrimidines.] |
| Cetuximab-IRDye 800CW | NCIT_C112499 | [An immunoconjugate comprised of the recombinant chimeric monoclonal antibody cetuximab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW (cetuximab-IRDye 800) with potential imaging use. The antibody moiety of cetuximab-IRDye 800 binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, IRDye 800 may be detected using NIR imaging, which facilitates the visualization and quantification of EGFR-expressing tumor cells. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various tumor types.] |
| UCP1 wt Allele | NCIT_C112493 | [Human UCP1 wild-type allele is located within 4q28-q31 and is approximately 9 kb in length. This allele, which encodes mitochondrial brown fat uncoupling protein 1, is involved in thermogenic proton transport. Polymorphism in the gene is associated with susceptibility to both obesity and type II diabetes mellitus.] |
| UCP1 Gene | NCIT_C112492 | [This gene plays a role in proton transport.] |
| Mitochondrial Brown Fat Uncoupling Protein 1 | NCIT_C112494 | [Mitochondrial brown fat uncoupling protein 1 (307 aa, ~33 kDa) is encoded by the human UCP1 gene. This protein plays a role in thermogenesis.] |
| Autologous Lymphoid Effector Cells Specific Against Tumor Cells | NCIT_C112495 | [A preparation of cytotoxic, autologous lymphoid effector cells specifically targeted towards tumor cells, with potential immunomodulating and antineoplastic activities. The autologous lymphoid effector cells are prepared by drawing a blood sample containing the required precursors for CD4+ helper T-cells, CD8+ cytotoxic T-cells, and natural killer (NK) cells from a cancer patient. The precursor cells are activated, selected and expanded to generate mature autologous lymphoid effector cells with the potential for enhanced tumor recognition. Upon readministration into the patient, the autologous lymphoid effector cells may induce both humoral and cellular immune responses against tumor cells. This may result in the immune-mediated inhibition of tumor cell proliferation, which leads to tumor cell death.] |
| Fluorine F 18 FDHT | NCIT_C112496 | [A radioconjugate containing a derivative of the androgen testosterone, 16-beta-fluoro-5-alpha-dihydrotestosterone (FDHT), labeled with the radioisotope fluorine F18 (18F-FDHT), with potential use as an imaging agent for positron emission tomography (PET). Upon administration, 18F-FDHT binds to the androgen receptor (AR). Upon PET imaging, AR-expressing prostate tumor cells can be imaged and assessed.] |
| CCSER1 wt Allele | NCIT_C112490 | [Human CCSER1 wild-type allele is located 4q22.1 and is approximately 1475 kb in length. This allele, which encodes serine-rich coiled-coil domain-containing protein 1, may play a role in mitosis. Deletion mutation of the gene is associated with various neoplasms.] |
| Serine-Rich Coiled-Coil Domain-Containing Protein 1 | NCIT_C112491 | [Serine-rich coiled-coil domain-containing protein 1 (900 aa, ~100 kDa) is encoded by the human CCSER1 gene. This protein may be involved in mitosis.] |
| Sarcoma of the Orbit pTX TNM Finding v7 | NCIT_C88811 | [Sarcoma of the orbit in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)] |
| Sarcoma of the Orbit Pathologic Primary Tumor TNM Finding v7 | NCIT_C88810 | [A pathologic finding about one or more characteristics of sarcoma of the orbit, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.] |
| Sarcoma of the Orbit pT0 TNM Finding v7 | NCIT_C88812 | [Sarcoma of the orbit with no evidence of a primary tumor. (from AJCC 7th Ed.)] |
| Sarcoma of the Orbit pT1 TNM Finding v7 | NCIT_C88813 | [Sarcoma of the orbit with tumor measuring 15 mm or less in greatest dimension. (from AJCC 7th Ed.)] |
| Sarcoma of the Orbit pT2 TNM Finding v7 | NCIT_C88814 | [Sarcoma of the orbit with tumor measuring more than 15 mm in greatest dimension without invasion of globe or bony wall. (from AJCC 7th Ed.)] |
| CDISC Questionnaire PDDS Test Name Terminology | NCIT_C112446 | [Test names of questionnaire questions associated with the Patient Determined Disease Steps (PDDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).] |
| CDISC Questionnaire Terminology | NCIT_C100110 | [The terminology subset that includes terms pertaining to the CDISC questionnaire terminology.] |